At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ASND Ascendis Pharma A/S
Pre-Mkt 08-31 07:51:47 EDT
247.91
-1.45
-0.58%
盘前246.00
-1.91-0.77%
07:09 EDT
High250.23Low246.30Vol314.79K
Open248.11D1 Closing249.36Amplitude1.58%
Mkt Cap16.41BTradable Cap16.25BTotal Shares66.19M
T/O77.96MT/O Rate0.48%Tradable Shares65.54M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties
Reuters  ·  50 minutes ago
Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties
Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)
THOMSON REUTERS  ·  52 minutes ago
Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)
Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.
Dow Jones  ·  18:42
Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma
TIPRANKS  ·  17:15
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma
Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma
THOMSON REUTERS  ·  16:36
Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma
BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel
MT Newswires Live  ·  15:53
BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel
Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries
THOMSON REUTERS  ·  14:00
Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries
HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target
MT Newswires Live  ·  08-27
HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target
Ascendis Pharma initiated with a Buy at H.C. Wainwright
TIPRANKS  ·  08-27
Ascendis Pharma initiated with a Buy at H.C. Wainwright
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026
Reuters  ·  08-26
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026
THOMSON REUTERS  ·  08-26
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026
Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside
Simply Wall St.  ·  08-25
Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside
Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares
Reuters  ·  08-19
Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares
Eyconis Announces Initiation of First-in-Human Clinical Trial of Eyc-0305 in Treatment-NaÏVe Wet Age-Related Macular Degeneration Patients
THOMSON REUTERS  ·  08-18
Eyconis Announces Initiation of First-in-Human Clinical Trial of Eyc-0305 in Treatment-NaÏVe Wet Age-Related Macular Degeneration Patients
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next
Simply Wall St.  ·  08-16
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says
MT Newswires Live  ·  08-14
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says
Ascendis Pharma is Maintained at Overweight by Barclays
Dow Jones  ·  08-14
Ascendis Pharma is Maintained at Overweight by Barclays
Ascendis Pharma (ASND) Receives a Buy from Cantor Fitzgerald
TIPRANKS  ·  08-14
Ascendis Pharma (ASND) Receives a Buy from Cantor Fitzgerald
RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-14
RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
TIPRANKS  ·  08-14
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

Introduction

Company Name.
Ascendis Pharma A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Issue price:
--